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Abstract 
Resistance to radiotherapy due to insufficient cancer cell death is a significant cause of 
treatment failure in non-small cell lung cancer (NSCLC). The endogenous caspase-8 
inhibitor, FLIP, is a critical regulator of cell death that is frequently overexpressed in NSCLC 
and is an established inhibitor of apoptotic cell death induced via the extrinsic death receptor 
pathway. Apoptosis induced by ionizing radiation (IR) has been considered to be mediated 
predominantly via the intrinsic apoptotic pathway; however, we found that IR-induced 
apoptosis was significantly attenuated in NSCLC cells when caspase-8 was depleted using 
RNA interference (RNAi), suggesting involvement of the extrinsic apoptosis pathway. 
Moreover, overexpression of wild-type FLIP, but not a mutant form that cannot bind the 
critical death receptor adaptor protein FADD, also attenuated IR-induced apoptosis, 
confirming the importance of the extrinsic apoptotic pathway as a determinant of response to 
IR in NSCLC. Importantly, when FLIP protein levels were down-regulated by RNAi, IR-
induced cell death was significantly enhanced. The clinically relevant histone deacetylase 
(HDAC) inhibitors vorinostat and entinostat were subsequently found to sensitize a subset of 
NSCLC cell lines to IR in a manner that was dependent on their ability to suppress FLIP 
expression and promote activation of caspase-8. Entinostat also enhanced the anti-tumor 
activity of IR in vivo. Therefore, FLIP down-regulation induced by HDAC inhibitors is a 
potential clinical strategy to radio-sensitize NSCLC and thereby improve response to 
radiotherapy. Overall, this study provides the first evidence that pharmacological inhibition of 
FLIP may improve response of NCSLC to IR. 
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Introduction   
Lung cancer is the most common cause of cancer death worldwide. Non-small cell lung 
cancer (NSCLC) represents approximately 80% of lung cancer deaths, with around 86,000 
deaths per year in the USA (1). Radical chemo-radiotherapy is delivered with curative intent 
in localised and inoperable disease, but local recurrence after treatment is high, with an 
overall 5 year survival of 7-20% (2). The complexity of the underlying molecular mechanisms 
of radioresistance and tumor heterogeneity in NSCLC has hindered translation of novel 
therapies to clinic, and there remains an urgent need for better radiation-based treatment 
options in NSCLC. Recent advances in the development of molecularly-targeted therapies 
coupled with new technological approaches in radiotherapy delivery have created the 
opportunity for novel combination therapies with significant potential for improved treatment 
options for NSCLC (3). 
 
Radiotherapy is currently one of the most effective cancer treatments, with over half of all 
cancer patients and around 76% of all lung cancer cases prescribed radiotherapy at some point 
in their treatment regimen (4). Although technological advances have improved pathological 
response rates to advanced conformal therapies compared to standard techniques, there is 
need to further improve therapeutic ratio by minimising the probability of complications in 
surrounding normal tissues (3,5). Evasion of cell death is a mechanism by which cancer cells 
resist anti-cancer therapy (6); targeting resistance to cell death is therefore a potential strategy 
to preferentially sensitize tumor cells to ionizing radiation (IR)-induced cell death and thereby 
improve response rates to radiotherapy in NSCLC. 
 
One of the mechanisms by which tumors evade apoptosis is by overexpression of anti-
apoptotic proteins such as the caspase-8 inhibitor FLIP, which blocks induction of apoptosis 
mediated by death receptors such as Fas, DR4 (TRAIL-R1) and DR5 (TRAIL-R2) (7,8). FLIP 
inhibits homo-dimerization, self-processing and activation of procaspase-8 at the death-
inducing signalling complexes (DISCs) formed following activation of these receptors. FLIP 
also blocks apoptosis induced by the DISC-related cytoplasmic caspase-8-activating 
platforms TNFR1 Complex II and the Ripoptosome (9,10). Importantly, we have previously 
reported that FLIP is frequently overexpressed in NSCLC, and this overexpression correlates 
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with poor prognosis (11). Moreover, we and others have shown that FLIP is an important 
regulator of resistance to chemotherapy in a number of cancers, including NSCLC (11-14).  
 
In this study, we investigated FLIP and caspase-8 as determinants of response to IR-induced 
cell death in NSCLC. We found that FLIP-mediated regulation of caspase-8-induced cell 
death is an important determinant of resistance to IR. Moreover, in a subset of NSCLC 
models, FLIP-mediated resistance to IR-induced apoptosis can be overcome by HDAC 
inhibitors that down-regulate FLIP expression. These results describe for the first time the 
importance of FLIP as a potentially targetable determinant of resistance to IR in NSCLC. 
 
 
Materials & Methods 
Reagents 
Vorinostat (SAHA: suberoylanilide hydroxamic acid) and entinostat (MS-275) were 
purchased from Selleck Chemicals (Newmarket, UK) and were resuspended in the vehicle 
dimethyl sulfoxide (DMSO) at a stock concentration of 10mM. Aliquots of 100μL were 
stored at -20°C. 
 
Cell lines and cell culture 
The A549, NCI-H460 (H460), NCI-H1373 (H1373) and CCD-34Lu (34Lu) cell lines were 
obtained from ATCC (Teddington, UK) and HCC15 from the Leibniz Institute DSMZ 
(Braunschweig, Germany). ATCC authenticate their cell lines using Short Tandem Repeat 
(STR) profiling, which is a rapid, reproducible and standardized PCR-based method. DSMZ 
cell lines undergo authentication by DNA profiling and mycoplasma detection/elimination 
and their human cell lines are subjected to additional immunological, cytogenetic and 
molecular biological characterization. Frozen cell stocks of A549, H460 and 34Lu cell lines 
were obtained in November 2012, while H1373 and HCC15 cells were obtained in September 
2015. After thawing, cells were maintained as previously described (15) and passaged no 
more than twice before new stocks were frozen down. All experiments were performed on 
low passage number cells. Stable FLIP overexpressing cell lines were generated as previously 
described (16). All cell lines were regularly screened for presence of mycoplasma using the 
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MycoAlert® Mycoplasma Detection Kit (Lonza, Basel, Switzerland).  
 
siRNA transfections 
Scrambed control (SC) siRNA, FLIP, caspase-8 and caspase-9 siRNAs were obtained from 
Dharmacon (Chicago, IL) and transfected as previously described (14, 17).  
 
Western blotting and Antibodies 
Cells were harvested and lysed in RIPA buffer and Western blotting was carried out as 
previously described (17). Antibodies used: FLIP (NF6) and caspase-8 (12F5) (both Alexis 
Biochemicals, San Diego, CA), Caspase 9 (Cell Signaling Technology, Beverly, MA, USA 
PARP (eBioscience, San Diego, CA), β-actin (Sigma-Aldrich, UK). 
 
Flow cytometry 
Cell death, cell cycle distribution and cell surface death receptor expression were determined 
as previously described (14,17). 
 
Caspase activity assays 
Caspase-Glo® 8 and Caspase-Glo® 3/7 assays (Promega, Southampton, UK) are luciferase-
based caspase activity assays. Protein cell lysates (5μg) were incubated with 25μL of 
Caspase-Glo® reagent in a total volume of 50µL on a 96 well plate. The plate was then 
incubated in the dark at room temperature with gentle agitation for 30 minutes before being 
analysed (Biotek Synergy 4 plate reader). 
 
Clonogenic Assays 
H460 and A549 cells were seeded at various densities in triplicate on 6 well plates. Following 
adherence, cells were treated with drug and/or irradiated. Plates were then incubated for 14 
days until colonies formed in control wells. Cells were fixed in ice cold 70% methanol, 
stained with 0.4% crystal violet stain solution, and colonies were manually counted. 
Surviving fractions were calculated from ≥3 independent experiments.  Survival fraction (SF) 
data after a radiation dose (D) are fit by a weighted, stratified, linear regression using Origin 
Pro version 8 according to the linear–quadratic formula: SF=exp(-αD-βD2). 
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In vitro and in vivo irradiation procedures 
In vitro experiments were performed with 225 kVp X-rays generated using a X-Rad 225 
generator (Precision X-ray Inc., North Bradford, CT) with a 2 mm copper filter. All quoted 
doses are the absorbed dose in water 50 cm from the radiation source at a dose rate of 0.591 
Gy/min. In vivo experiments were performed using a small animal radiotherapy research 
platform (SARRP, Xstrahl Life Sciences, UK). Prior to cone beam computed tomography 
(CBCT) imaging, mice were anesthetized by intra-peritoneal injection of xylazine/ketamine. 
Animals were imaged at 50 kV and 0.6 mA. Treatment planning was performed using 
Muriplan (Xstrahl Life Sciences, UK) to achieve uniform dose distributions across the tumor 
target by delivering two parallel opposed 10 x 10 mm beams and avoiding critical structures. 
Therapeutic radiation doses were delivered 10-15 min after CT imaging. SCID mice were 
injected with 2 million A549 cells/flank in the dorsal position. After tumors had established 
(d7), mice were treated with 10 mg/kg entinostat daily for 10 days (up to d17) and a total of 
12 Gy IR was delivered using parallel-opposed beams in daily 2 Gy fractions for 3 days (from 
d10-d12). Experimental endpoints for individual animals were defined by tumor volume 
exceeding 400 mm3 or animals losing in excess of 10% of their body weight at the start of the 
experiment. Animals received food and water ad libitum. All experimental procedures were 
carried out in accordance with United Kingdom Home office approved protocols for in vivo 
experimentation. 
 
Statistics  
GraphPad Prism v5 software was applied for statistical analysis. Student’s t-test and two-way 
analysis of variance (ANOVA) with Bonferroni post-tests were performed with labelled 
significance as; * denotes 0.01<P<0.05; ** denotes 0.001<P<0.01; *** denotes P<0.001. 
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Results 
Radiation induced cell death is dependent on the extrinsic apoptotic pathway.  The response 
to IR of two NSCLC cell line models, H460 and A549 were initially assessed. The induction 
and repair of DNA double strand breaks following exposure to a 1 Gy dose of IR was 
assessed by quantification of IR-induced γH2AX foci. γH2AX foci were rapidly induced 30 
minutes post-treatment and resolved within 24 hours (Supplementary Figure 1A). In both cell 
lines, a decreased proportion of cells in the G1 phase of the cell cycle with corresponding 
increase in S and G2/M phases was observed 4-8 hours after a 2 Gy dose of IR. However, 
these cell cycle perturbations were also resolved at 24 h (Supplementary Figure 1B). Of note, 
up to 72 h post-treatment, there was relatively little cell death induction in response to 2 Gy 
IR as indicated by analysis of the sub-G1 apoptotic population (Supplementary Figure 1C). 
Increasing the dose to 5 and 8 Gy significantly increased apoptosis in H460 cells at 72 hours; 
however, the increase in apoptosis in A549 cells in response to these high doses was less 
marked (Supplementary Figure 1C). These relative contrasting sensitivities to radiation-
induced apoptosis were reflected at the cell survival level, with H460 cells being more 
radiosensitive than A549 cells (Supplementary Figure 1D). These relative radio-sensitivities 
are in agreement with the published literature (18) and correlate with their relative sensitivity 
to TRAIL-induced apoptosis and their expression levels of FLIP (16). 
 
Assessment of caspase activity revealed that exposure to IR results in dose-dependent 
increases in both caspase-8 and caspase-3/7 activity in H460 cells (Supplementary Figure 
2A). Importantly, RNAi-mediated procaspase-8 depletion was demonstrated to have a 
significant protective effect against IR-induced apoptosis 48 (Figure 1A) and 72 hours 
(Supplementary Figure 2B) post treatment, suggesting the involvement of the extrinsic 
apoptotic pathway. In contrast, down-regulation of procaspase-9 failed to rescue apoptosis 
induction in response to IR in H460 cells (Figure 1B). Overexpression of either FLIP(L) or 
FLIP(S) inhibited IR-induced apoptosis in H460 cells, with the overexpression of FLIP(S) 
having the more profound effect (Figure 1C). In contrast, a mutant form of FLIP(S), in which 
its critical Phe114 residue is mutated to Ala rendering it incapable of binding to FADD (19), 
was unable to inhibit IR-induced apoptosis (Figure 1C). These effects were reflected in 
clonogenic survival assays, with the wild-type FLIP(L) and FLIP(S) overexpressing models 
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exhibiting increased radioresistance, whereas the F114A FLIP(S) overexpressing model was 
as radiosensitive as the Empty Vector (EV) control cell line (Figure 1C and D). These results 
indicate that FLIP- and FADD-dependent caspase-8 activation regulate IR-induced apoptosis 
in this NSCLC cell line model.  
 
FLIP siRNA synergizes with IR to induce apoptosis. To further assess the role of FLIP in 
regulating IR-induced apoptosis, we down-regulated both major splice forms using a pan-
FLIP-targeting siRNA (FT). Consistent with our previous observations, simultaneous down-
regulation of both FLIP splice forms induced apoptosis in H460 cells as indicated by PARP 
cleavage (Figure 2A). IR exposure in control siRNA (SC) transfected cells induced a modest 
dose-dependent increase in PARP cleavage. Most notably, IR significantly enhanced the 
PARP cleavage observed in FLIP-depleted cells; moreover, there was as much PARP 
cleavage in FT siRNA transfected cells exposed to 2 Gy as those exposed to 5 and 8 Gy 
(Figure 2A). These results were confirmed quantitatively using caspase activity assays: 
silencing FLIP enhanced caspase-8 and caspase-3/7 activity in H460 cells, and this was 
significantly enhanced by exposure to 2 Gy, with little further increase when the IR dose was 
elevated (Figure 2B). Quantitative assessment of cell death induction also indicated that FLIP 
silencing enhanced IR-induced apoptosis; moreover, the levels of cell death were similar 
when FLIP was depleted before or after IR exposure (Figure 2C). In addition, clonogenic 
survival of FLIP-depleted irradiated H460 cells was significantly diminished compared to 
control siRNA transfected cells (Figure 2D).  
 
We extended these analyses to additional NSCLC models. Similar results to those obtained in 
the H460 cell line were observed in A549 cells, with FLIP silencing significantly enhancing 
radiation-induced apoptosis and decreasing clonogenic survival (Figures 3A-B). In light of the 
importance of the extrinsic apoptotic pathway in regulating IR-induced cell death in A549 and 
H460 cells, we assessed expression of the receptors that can mediate FLIP/caspase-8-
dependent apoptosis, namely TNFR1, Fas/CD95, TRAIL-R1 and TRAIL-R2. All 4 receptors 
were expressed on the surface of each cell line, with IR increasing expression of each 
receptor, most notably Fas/CD95 (Supplementary Figure 3). These results are consistent with 
IR-induced activation of the extrinsic apoptotic pathway. 
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We subsequently analyzed NSCLC cell line models harboring a mutation in the gene 
encoding the inflammasome subunit NLRP3, which has previously been linked to hyper-
sensitivity to RNAi-mediated FLIP depletion (20). In agreement with the literature, NLRP3 
mutated HCC15 and H1373 cell lines were found to be highly sensitive to FLIP-depletion as 
determined by PARP cleavage (Figure 3C). Increased sensitivity to IR-induced apoptosis was 
difficult to assess by PARP cleavage given the extent of apoptosis induced by FLIP silencing 
alone; however, quantitative assessment by Annexin V/propidium iodide staining indicated 
that the combined effects were at least additive in these models (Figure 3D). 
 
HDAC inhibitors down-regulate FLIP and enhance radiation-induced apoptosis. The results 
described above clearly indicate that FLIP down-regulation sensitizes NSCLC cells to IR-
induced apoptosis. Previous reports from our group have shown that HDAC inhibitors with 
anti-HDAC1-3 activity are efficient suppressors of FLIP expression operating at both 
transcriptional and post-transcriptional levels (11). In H460 cells treated with the pan-HDAC 
inhibitor SAHA, FLIP(L) and FLIP(S) were down-regulated (Figure 4A). Moreover, SAHA 
treatment significantly sensitized H460 cells to IR-induced apoptosis, but had no impact on 
IR-induced apoptosis induction in the 34Lu normal lung fibroblast cell line (Figure 4B); we 
have previously shown that SAHA only downregulates FLIP expression in 34Lu cells at 
higher concentrations (≥ 10µM) (11). In addition, in H460 cells pre-treated with SAHA for 
6h, IR-induced caspase-3/7 activation was significantly enhanced (Figure 4C). These effects 
were reflected in clonogenic survival assays, which also demonstrated the radio-sensitizing 
effects of SAHA in the H460 cell line model (Figure 4D). Moreover, different treatment 
schedules of IR and SAHA were similarly effective in reducing clonogenic survival 
(Supplementary Figure 4A).  
 
SAHA is also an effective inhibitor of FLIP expression in A549 cells (11) and also sensitized 
these cell to IR (Figure 5A and Supplementary Figure 4B). Furthermore, SAHA down-
regulated FLIP expression in HCC15 cells albeit to a lesser extent than in H460 and A549 
cells, but had no effect on FLIP expression in the H1373 cell line (Figure 5B). This correlated 
with the relative effects of SAHA/IR combinations on apoptosis induction, with HCC15 more 
sensitive to the combination treatment than H1373 (Figure 5C).  
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Given the multiple modes of action of HDAC inhibitors (21,22), we used siRNA to deplete 
procaspase-8 expression (Figure 5D) and FLIP overexpressing cells (Figure 5E) to assess the 
relative importance of the FLIP/caspase-8 axis on cell death induced by the IR/SAHA 
combination. We found that cell death induction was significantly inhibited by procaspase-8 
depletion (Figure 5D). SAHA was unable to down-regulate expression of the exogenous FLIP 
proteins expressed in H460 cells (Figure 5E), due to activation of the transgenic promoter 
(data not shown). This allowed us to assess the importance of FLIP down-regulation for the 
combined effects of SAHA and IR. Notably, wild-type FLIP(S) overexpression significantly 
inhibited SAHA/IR-induced apoptosis, whereas the F114A mutant that has impaired ability to 
bind to FADD was unable to inhibit apoptosis induced by the combination treatment. FLIP(L) 
overexpression also inhibited apoptosis induction in response to SAHA/IR, although to a 
lesser extent than FLIP(S) overexpression; this may reflect the lower level of FLIP(L) 
overexpression compared to FLIP(S) in the models at this time. Collectively, these results 
demonstrate the importance of FLIP down-regulation and caspase-8 activation in mediating 
the effects of the SAHA/IR combination treatment. 
 
The benzamide entinostat (MS-275/SNDX-275) is an HDAC1/2/3-selective inhibitor that has 
been clinically assessed in NSCLC (23). Entinostat has a significantly longer plasma half-life 
than the hydroxamic acid-based HDAC inhibitors such as SAHA (23). Consistent with our 
previous observations (11), entinostat also effectively downregulated FLIP in H460 and A549 
(Figures 6A and C), and efficiently down-regulated FLIP expression in HCC15 cells, but not 
H1373 (Figure 5B). Moreover, similar to SAHA, entinostat enhanced IR-induced apoptosis in 
both H460 and A549 cell lines (Figures 6B and D). Given its relative radioresistance, we 
assessed whether the sensitivity of A549 cells to IR could be enhanced in vivo by entinostat. 
A549 xenografts in SCID mice were directly irradiated with a total dose of 12 Gy delivered as 
3 fractions of 4 Gy over 3 days delivered using parallel opposed beam geometry using a Small 
Animal Radiotherapy Research Platform (SARRP) and co-treated with 10 mg/kg entinostat. 
Both radiation alone and entinostat alone significantly retarded tumor growth (Figure 6E). 
The effects of the combination treatment were similar to the individual treatments up to d28, 
after which the co-treatment had a greater impact on tumor growth than the single agent 
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treatments, suggesting that long-term growth is more efficiently suppressed by the co-
treatment (Figure 6E). 
 
Discussion 
NSCLC cancer is a significant international public health burden. The prognosis for patients 
with NSCLC remains very poor, with overall survival after 5 years for stages Ia/b, II, IIIa, IIIb 
and IV disease of 49-45, 30, 14, 5 and 1% respectively (24). There is an urgent need for better 
treatment options. For localised and inoperable forms of the disease, radiotherapy plays a 
critical role; however, local recurrence after treatment is common due to radio-resistance. 
There are multiple mechanisms of radio-resistance, including resistance to IR-induced cell 
death (25,26). Improved understanding of the molecular mechanisms underpinning radio-
resistance in NSCLC is needed to enable the development of novel approaches to improve the 
efficacy of radiation-based treatment. In this study, we have identified the anti-apoptotic 
protein FLIP as an important mediator of radio-resistance. 
 
FLIP is a key regulator of apoptosis that heterodimerizes with procaspase-8 at the death-
inducing signalling complexes (DISCs) formed following ligation of death receptors such as 
TRAIL-R1 and -R2 and Fas/CD95, thereby inhibiting the homodimerization of procaspase-8 
that is a prerequisite for caspase-8 activation (27). FLIP has also been demonstrated to 
regulate caspase-8 activation at TNFR1 Complex IIa, IIb and the Ripoptosome (28). These 
important complexes regulate cell fate downstream of TNFR1 ligation (Complexes IIa and b) 
and in response to chemotherapy and IAP antagonists (Ripoptosome) (9,29). Complexes IIb 
and the Ripoptosome contain RIPK1, which regulates programmed necrosis (“necroptosis”) 
via RIPK3 and MLKL (30,31). The heterodimer formed between FLIP(L) and procaspase-8 at 
these complexes has enzymatic activity, which although unable to initiate apoptosis, 
suppresses necroptosis by cleaving RIPK1 (32). In addition to regulating apoptosis and 
necroptosis, FLIP has also been identified as an important regulator of autophagy through 
direct interactions with ATG3 (33). 
 
Given its key roles in promoting cell survival, it is unsurprising that numerous clinical studies 
have demonstrated that FLIP is frequently overexpressed in cancer and that patients with 
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tumors with elevated levels of FLIP tend to have a poorer prognosis (34,35). We previously 
reported that FLIP is overexpressed in NSCLC and that high cytoplasmic FLIP expression 
correlates with poorer prognosis in a cohort of stage I-III NSCLC of mixed histology (roughly 
50% adenomatous and 50% squamous) (11). Importantly, we and others have shown that 
FLIP not only inhibits apoptosis induced directly via death receptor activation, but also 
apoptosis induced by anti-cancer drugs in a number of cancers, including pre-clinical models 
of NSCLC (11,15,36); therefore, FLIP is a critical determinant of drug resistance. In contrast, 
there has been a lack of studies investigating the role of FLIP in regulating IR-induced 
apoptosis, possibly because early studies in Jurkat cells reported that FLIP was unable to 
prevent IR-induced apoptosis in this model (37). While some studies have unsurprisingly 
shown that FLIP regulates apoptosis in response to combined treatment with IR and TRAIL 
(38), we are aware of only one other study that has suggested a direct role of FLIP in 
regulating IR-induced cell death: Luo et al. previously reported that silencing of FLIP 
sensitizes HeLa cells to both radiotherapy and chemotherapy (39). However, to our 
knowledge there are no other studies that have evaluated the role of FLIP in modulating 
response to IR in NSCLC.  
 
The current study provides strong evidence that FLIP-FADD-Caspase-8 complexes (40) are 
important regulators of radiation-induced cell death in pre-clinical models of NSCLC: FLIP 
depletion was found to enhance IR-induced apoptosis, while procaspase-8 depletion or FLIP 
overexpression abrogated IR-induced cell death. Moreover, FLIP’s ability to inhibit IR-
induced cell death was found to be dependent on its ability to interact with FADD. All of the 
experiments reported in this study were carried out in the absence of co-treatment with death 
ligands such as TRAIL and FasL/CD95L, and these models do not express detectable levels 
of death ligands ((33) and unpublished observations). Thus, the FLIP-FADD-Caspase-8 
complexes induced by IR are not classical DISCs activated via the extrinsic pathway 
following death ligand binding. In the clinical setting, interactions between immune effector 
cells expressing TRAIL, FasL/CD95 and TNFα and tumor cells are likely to further enhance 
the importance of FLIP-FADD-Caspase-8 complexes in determining the outcome of 
radiotherapy. 
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HDAC inhibitors such as vorinostat and entinostat prevent the deacetylation of histone and 
non-histone proteins and have been shown to sensitise cancer cells to chemotherapy and IR 
(41-43). In this study, we demonstrate that HDAC inhibitors enhance the in vitro and in vivo 
efficacy of IR in NSCLC models. Our group previously demonstrated that HDAC inhibitors 
downregulate FLIP in colorectal cancer models at the post-translational level by disrupting its 
interaction with Ku70, resulting in FLIP ubiquitination and degradation via the ubiquitin-
proteasome system (17). We also previously demonstrated that HDAC inhibitors effectively 
suppress FLIP expression at the transcriptional and post-transcriptional levels in H460 and 
A549 NSCLC cells (11). In this study, we report that HDAC inhibitors efficiently down-
regulate FLIP in a subset of NSCLC pre-clinical models and that this promotes IR-induced, 
caspase-8-mediated apoptosis in these models. 
 
In conclusion, we report that FLIP is a key determinant of radio-resistance in pre-clinical 
models of NSCLC; this is an important finding given the frequent over-expression of FLIP in 
this disease and suggests that FLIP expression is a potential predictive biomarker of response 
to radiotherapy in NSCLC. We have previously reported that procaspase-8 is also 
overexpressed in a significant number of NSCLCs rendering them sensitive to apoptosis when 
FLIP is downregulated (11,15). In this study, we demonstrate that FLIP expression can be 
down-regulated in at least a subset of NSCLCs using clinically relevant HDAC inhibitors and 
that this promotes IR-induced apoptosis. This suggests that HDAC inhibitor/IR combination 
therapy may be particularly effective in NSCLCs that overexpress FLIP and/or procaspase-8. 
This radio-sensitization approach could be combined with stereotactic delivery of 
radiotherapy to minimize toxicity. However, understanding the molecular determinants of 
HDAC inhibitor-induced down-regulation of FLIP in NSCLC will be needed to enable patient 
selection. As an alternative approach, small molecules that specifically target FLIP more 
directly than HDAC inhibitors may have wider application in combination with IR in 
NSCLC. 
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Figure Legends 
 
Figure 1. IR-induced cell death in H460 cells is Caspase-8 and FLIP-dependent.  A H460 
cells were transfected with 20 nM scrambled control (SC) or caspase-8-targeted siRNA and 
irradiated at 2, 5 and 8 Gy. Western blotting confirmed procaspase-8 downregulation. DNA 
content of cells was analysed by flow cytometry and the sub‐G1 population (DNA content 
<2N) was determined as a measurement of apoptosis 48 hours post-IR.  B H460 cells were 
transfected with 20 nM scrambled control (SC), caspase-8- or caspase-9-targeted siRNA and 
irradiated at 2, 5 and 8 Gy. Western blotting confirmed procaspase-8 and procaspase-9 
downregulation. Cell death was assessed by Annexin V/propidium iodide flow cytometry 48 
hours post-IR.  C H460 cells overexpressing wild-type FLIP(L), FLIP(S) or FLIP(S) F114A 
were treated with 2 or 5 Gy IR for 72 h. DNA content of cells was analysed by flow 
cytometry and the sub‐G1 population was determined. EV denotes the control empty vector 
cell line.  D Clonogenic survival assays performed in EV, FLIP(L), FLIP(S) and FLIP(S) 
F114A H460 cells treated with the indicated doses of IR and incubated for 14 days . A colony 
is defined as a group of >50 cells. Surviving fractions were calculated from 3 independent 
experiments, and curves were fitted using linear-quadratic model. 
 
Figure 2. Downregulation of FLIP enhances IR-induced death in H460 cells.  A H460 
cells were transfected with 10 nM FLIP-targeted (FT) siRNA 24 h before IR and were 
harvested 48 h post-IR. Western blot analysis was used to detect FLIP and PARP protein 
expression levels.  B Caspase-8 and caspase-3/7 activity was assessed in H460 cells 
transfected with 10 nM FT siRNA for 24 h prior to IR for 48 h.  C H460 cells were 
transfected with 10 nM  of SC or FT siRNA and treated with IR in two different schedules: IR 
24 h after siRNA transfection (siFLIP/IR) or IR 24 h before transfection (IR/siFLIP). Cell 
death was assessed by Annexin V/propidium iodide flow cytometry 24 h after the final 
treatment.  D Clonogenic survival assays performed in H460 cells transfected with FT or 
control siRNAs, treated with the indicated doses of IR and incubated for 14 days.  Surviving 
fraction was calculated from 3 independent experiments, and curves were fitted using linear-
quadratic model. 
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Figure 3. FLIP is a determinant of IR resistance in A549 and NLRP3 mutated HCC15 
and H1373 NSCLC models.  A. A549 cells were transfected with 10nM scrambled control 
(SC) or FLIP-targeted (FT) siRNA and treated with IR in two different schedules: IR 24 h 
after siRNA transfection (siFLIP/IR) or 24 h before silencing (IR/siFLIP). Cell death was 
assessed by Annexin V/propidium iodide method a further 24 h after the final treatment. 
Western blot analysis was used to confirm FT siRNA-mediated FLIP down-regulation.  B 
Clonogenic survival assays performed in A549 cells transfected with FT or control siRNAs, 
treated with the indicated doses of IR and incubated for 14 days. Surviving fraction was 
calculated from 3 independent experiments, and curves were fitted using linear-quadratic 
model.  C Western blot analysis of FLIP expression and PARP cleavage in HCC15 and 
H1373 NLRP3 mutant NSCLC cell lines cells transfected with 10 nM FT siRNA for 6 h prior 
to treatment with IR for 48 h.  D Annexin V/propidium iodide assessment of apoptosis in 
HCC15 and H1373 cell lines transfected with 10 nM FT siRNA for 6 h prior to treatment with 
IR for 72 h. 
 
Figure 4. The pan-HDAC inhibitor vorinostat (SAHA) downregulates FLIP and 
enhances IR-induced cell death.  A Western blot analysis of FLIP protein expression in 
H460 cells treated with 1 µM SAHA for 48 h.  B H460 and 34Lu cells were treated with the 
indicated doses of SAHA for 24 h prior to exposure to 5 and 8 Gy IR. The DNA content of 
the cells was determined 72 h post-IR by flow cytometry, and the sub-G1 apoptotic 
population (DNA content <2N) determined.  C Caspase-3/7 activity in H460 cells treated with 
1μM SAHA for 6 h and irradiated with the indicated doses of IR for a further 48 h.  D 
Clonogenic survival assays performed in H460 cells treated with SAHA and the indicated 
doses of IR. The surviving fraction after 14 days was calculated from 3 independent 
experiments. 
 
Figure 5. Cell death induced by IR/SAHA combination therapy is FLIP and caspase-8-
dependent.  A Annexin V/propidium iodide assessment of apoptosis in A549 cells 48 h post-
IR. Cells were pre-treated with SAHA for 24 h and irradiated with the indicated doses of IR. 
B Western blot analysis of FLIP protein expression in HCC15 and H1373 cell lines treated 
with 1 µM SAHA for 24 h.  C Annexin V/propidium iodide assessment of apoptosis in 
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HCC15 and H1373 cell lines treated with 1 µM SAHA 6 h prior to treatment with IR; cells 
were analysed 72 h post-IR.  D H460 cells were transfected with 20 nM scrambled control 
(SC) or caspase-8 targeted siRNA. After 24 h, cells were treated with 2.5 µM SAHA and 
incubated for additional 24 h, after which the cells were exposed to IR. The cells were then 
analysed 48 h post-IR. Western blotting confirmed procaspase-8 downregulation. DNA 
content of the cells was determined by flow cytometry, and the sub-G1 population (DNA 
content < 2N) was determined as a measurement of apoptosis.  E Empty vector (EV), FLIP(L) 
WT (FL) , FLIP(S) WT (FSWT) and FLIP(S) F114A MT (FSMT) overexpressing cells were 
pre-treated with 1μM SAHA and then irradiated 24 h later. The sub-G1 apoptotic population 
was quantified 72 h post-IR by flow cytometry. 
 
Figure 6. The HDAC1-3 selective inhibitor entinostat enhances IR-induced cell death in 
vitro and in vivo.  A Western blot analysis of FLIP protein expression in H460 cells treated 
with 2.5 µM entinostat for 24 h.  B. H460 cells were treated 5 Gy of IR, after 48 h cells were 
then treated with 5 µM entinostat. After a further 24 h, Annexin V/propidium iodide 
assessment of apoptosis was performed.  C Western blot analysis of FLIP protein expression 
in A549 cells treated with 2.5 µM entinostat for 72 h.  D A549 cells were treated with 2.5 or 5 
µM entinostat for 24h and then exposed to IR. After a further 48h, Annexin V/propidium 
iodide assessment of apoptosis was performed.  E Assessment of A549 xenograft growth in 
response to individual and combined treatment with entinostat and IR. Mice were treated with 
10 mg/kg entinostat daily for 10 days (up to d17) and a total of 12 Gy IR was delivered using 
parallel-opposed beams in daily 2 Gy fractions for 3 days (from d10-d12). The treatment 
volumes on d7 prior to treatment and d36 at the end of the experiment are presented. 
 
 
A 
C 
Figure 1 
siSC  siC8 
Procaspase-8 
β-actin 
Dose/Gy 
SU
R
V
IV
IN
G
 F
R
A
C
TI
O
N
 
Dose/Gy 
D 
FL WT * 
FS WT ** 
FS F114A ns 
FL WT ** 
FS WT ** 
FS F114A ns 
FL WT *** 
FS WT *** 
FS F114A ns 
%
 S
u
b
-G
1
 
55kDa 
42kDa 
B 
si
 S
C
  
si
 C
8
 
si
 C
9
  
si
 S
C
 
si
 C
9
 
si
 C
8
 
Pre-IR 
Procaspase-8 
β-actin 
Procaspase-9 
Post-IR 
55kDa 
42kDa 
47kDa 
A 
  SC    FT     SC    FT    SC     FT    SC     FT    siRNA 
FLIP(L) 
FLIP(S) 
PARP 
β-actin 
 2             5              8            Dose/Gy   B 
C 
Figure 2 
D 
SC
siFLIP L+S
siFLIP L
siFLIP S
*** 
*** 
*** 
             
siFLIP 
siSC 
SU
R
V
IV
IN
G
 F
R
A
C
TI
O
N
 
Caspase-8                                      Caspase-3/7 
2              5            8                                           2           5            8          Dose/Gy 
*** 
*** *** 
*** ** 
*** 55kDa 
26kDa 
42kDa 
116kDa 
85kDa 
* ** 
* * 
FLIP(L) 
FLIP(S) 
β- actin 
   SC   siFLIP 
A549 
Figure 3 
SC
siFLIP L+S
siFLIP L
siFLIP S
* 
** 
*** 
siFLIP 
siSC 
A549 A549 B 
si
SC
  
si
FL
IP
 
si
SC
  
si
FL
IP
 
si
SC
  
si
FL
IP
 
si
SC
  
si
FL
IP
 
D 
Mock            5 Gy Mock            5 Gy 
Dose/Gy 
SU
R
V
IV
IN
G
 F
R
A
C
TI
O
N
 
si
SC
  
si
FL
IP
 
0 Gy       2 Gy          5 Gy         8 Gy     0 Gy       2 Gy          5 Gy         8 Gy     
si
SC
  
si
FL
IP
 
si
SC
  
si
FL
IP
 
si
SC
  
si
FL
IP
 
si
SC
  
si
FL
IP
 
si
SC
  
si
FL
IP
 
si
SC
  
si
FL
IP
 
si
SC
  
si
FL
IP
 
H1373 HCC15 
FLIP(L) 
FLIP(S) 
β-actin 
PARP 
C 
%
 A
N
N
EX
IN
 V
/P
I P
O
SI
TI
V
E 
A 
55kDa 
26kDa 
42kDa 
55kDa 
26kDa 
42kDa 
116kDa 
   85kDa 
SC SC siFLIP siFLIP SC SC siFLIP siFLIP
0
10
20
30
40
50
60
70
80
-             +            -           +                  -           +            -           +          -/+ 5 Gy
siFLIP / IR
IR / siFLIP
***
**
***
***
A B 
H460 
H460 
D 
55kDa 
26kDa 
42kDa 
-       +          1μM SAHA 
FLIP(L) 
  
  
FLIP(S) 
β-actin 
Figure 4 
D
o
se
/G
y 
Dose/Gy 
SU
R
V
IV
IN
G
 F
R
A
C
TI
O
N
 
%
 S
u
b
-G
1
 
C 
SAHA (μM)  
34Lu 
*** 
*** 
*** 
* 
%
 S
u
b
-G
1
 
SAHA (μM)  
1μM SAHA 
ns 
ns * 
* 
* 
H460 Caspase-3/7 activity 
DMSO   
  
Dose/Gy     
   
   
   
  R
LU
 ns 
* 
Figure 5 
A 
%
 S
u
b
-G
1
 
FLIP(L) 
FLIP(S) 
β-Actin 
C
o
n
tr
o
l 
D
M
SO
 
SA
H
A
  
HCC15 
D 
E 
A549 
0 2.5 5
0
10
20
30
40
50
60
SAHA (mM)
Dose/Gy
2
5
0
**
ns
ns
ns
%
	D
ea
d	
ce
lls
	(A
nn
/P
I	P
os
)
%
 A
N
N
EX
IN
 V
/P
I P
O
SI
TI
V
E 
C
o
n
tr
o
l 
D
M
SO
 
SA
H
A
  
H1373 
B 
C 
D
M
SO
 
SA
H
A
 
D
M
SO
 
SA
H
A
 
Mock                 5 Gy 
D
M
SO
 
SA
H
A
 
D
M
SO
 
SA
H
A
 
Mock                 5 Gy 
EV    FL    FSWT   FSMT     
-    +  -    +   -    +   -  +    
 
 
 
SAHA  
FLIP(L) 
 
FLIP(S) 
 β-actin 
 siSC     siC8 
PC8 
β-actin 
H460 
+/- SAHA 
M
S2
7
5
 
M
S2
7
5
 
55kDa 
42kDa 
26kDa 
55kDa 
42kDa 
26kDa 
55kDa 
42kDa 
Dose/Gy 
- + - + - + - +
0
10
20
30
40
50
60
0 2 5
SC
siCasp-8
***
ns
**
***
*
*
***
ns
8
Figure 6 
FLIP(L) 
FLIP(S) 
β-actin 
H460 
C 
FLIP(L) 
 
 
FLIP(S) 
β-actin 
-    +  
Entinostat (2.5μM) 
D E 
A549 A549 
A B 
-    +  
Entinostat (2.5μM) 
H460 
A549 xenograft model 
%
 A
N
N
EX
IN
 V
/P
I P
O
SI
TI
V
E 
ns (p=0.1) 
* 
%
 A
N
N
EX
IN
 V
/P
I P
O
SI
TI
V
E 
Vehicle     Entinostat Vehicle    Entinostat 
day 7 day 36 
55kDa 
42kDa 
26kDa 
55kDa 
42kDa 
26kDa 
0 2.5 5 0 2.5 5 0 2.5 5
0
10
20
30
40
50
60
2
5
Mock
Entinostat (mM)
***
**
****
**
Dose/Gy
**
